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Apolipoprotein Cs (apoC-1, apoC-II, and apoC-III) are
lipoprotein components that have regulatory effects on
enzymes involved in lipoprotein metabolism. Owing to their
low molecular weights, apoCs can adsorb onto and/or pass
through dialysis membranes. Our study determines the
consequence of hemodialysis (HD) on plasma concentrations
of apoCs and on the activities of enzymes modulated by
apoCs. Plasma samples were collected from 28 patients with
chronic renal failure before and after HD. Plasma apoC-II
levels were unchanged, whereas apoC-III levels were slightly
decreased in post-dialysis plasmas. The apoC-I content was
markedly reduced during HD. This was due to a significant
decrease in the apoC-I content of very low-density
lipoprotein (VLDL), whereas the apoC-I content of high-
density lipoprotein (HDL) was unchanged. Although HDL
bound apoC-I is thought to inhibit cholesterol ester transfer
protein, no change in the ability of pre- and post-dialysis
VLDL to interact with the transfer protein were observed.
Complementary experiments confirmed that VLDL-bound
apoC-I has no transfer protein inhibitory potential. In
contrast, an increase in the ability of post-dialysis apoC-I-poor
VLDL to act as substrate for lipoprotein lipase (LPL) was
found compared to pre-dialysis VLDL. Our study shows that
apoC-I losses during HD might be beneficial by improving
the ability of VLDL to be a substrate for LPL thus improving
plasma triglyceride metabolism.
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Coronary artery disease is a major cause of mortality and
morbidity in hemodialysis (HD) patients.1,2 Among other
risks factors, such as hypertension or diabetes, an altered
lipoprotein metabolism is thought to contribute significantly
to the accelerated development of atherosclerotic lesions in
these patients.3 The typical features of this dyslipidemia are
elevated triglyceride (TG) concentrations and low high-
density lipoprotein (HDL) cholesterol levels. In contrast,
total and low-density lipoprotein (LDL) cholesterol levels
usually remain in the normal range.4–7 Although the etiology
of the HD-associated dyslipidemia has not been fully
established, alterations of several enzymes involved in
lipoprotein metabolism are commonly observed. In parti-
cular, lipoprotein lipase (LPL) and hepatic lipase activities are
significantly decreased.8 As observed earlier in patients with
hypertriglyceridemia4 increased plasma TG level per se might
constitute a major contributor to elevated cholesteryl ester
transfer protein (CETP) activity in HD patients, and both
HD per se and chronic renal failure would contribute in a
complementary manner to these abnormalities.4 During HD,
heparin that is used as an anticoagulant to prevent clotting in
the extra corporeal devices releases LPL from its binding sites
at the vascular endothelium. It has been suggested that
repeated heparinization induces a subsequent leakage of LPL
that exceeds the rate of enzyme synthesis and thereby causes a
depletion of LPL pool.9–11 Besides lipase activities, increased
CETP-mediated transfers of TGs from very low-density
lipoprotein (VLDL) to LDL and HDL were also observed in
HD patients. In the two latter cases, abnormalities were
attributed mainly to the HD procedure, which led to both
LPL loss and CETP inhibitor deficiency.4,12 Elevated
concentrations of apoC-III in VLDL is also known to
constitute a prominent feature of dyslipidemia through LPL
inhibition in patients with chronic renal feature.13,14 In this
case, lipid abnormalities should be considered as a reflect of
chronic renal failure and not a consequence of the HD
treatment.
ApoCs, including apoC-I, apoC-II, and apoC-III, are low
molecular weight apolipoproteins, and they are components
of chylomicrons, VLDL, and HDL where they exert specific
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biological functions. In contrast to apoC-III, the metabolism
of apoC-I and apoC-II in HD has not been investigated in an
extensive manner. Nevertheless, alterations in apoC-I and
apoC-II levels in HD are important to consider because of
their potent inhibitory or stimulatory effects on a variety of
receptors and enzymes involved in lipoprotein metabolism.
ApoC-I inhibits the uptake of TG-rich lipoproteins via
hepatic receptors, particularly the LDL receptor-related
protein.15,16 In addition, ApoC-I is a weak activator of
lecithin cholesterol acyl transferase,17,18 and it has been
reported to inhibit plasma phospholipase A2,19 CETP,20 LPL,
and hepatic lipase.21,22 ApoC-II is a physiological activator of
LPL and as such it is required for efficient lipolysis of TG-rich
lipoproteins in the circulation.23 Although mostly associated
with circulating lipoprotein particles, apo Cs are able to
transfer freely between lipoprotein particles through aqueous
diffusion,24 and due to their low molecular weight, they can
diffuse through and/or absorb on dialysis membranes. ApoC
leakage during the dialysis procedure might then contribute
to alterations in lipoprotein metabolism in HD patients.
The aim of this study was to assess, in a comprehensive
way, the influence of HD per se on apoCs and to evaluate the
consequences on enzymes activities and plasma lipids. It is
reported that the plasma apoC-I concentration is mostly
modified in HD patients with chronic renal failure, resulting
from a significant loss of VLDL-associated apoC-I during
HD. Whereas pre- and post-dialysis VLDL did not differ in
their ability to interact with CETP, a significant increase in
the ability of post-dialysis, apoC-I-deprived VLDL to act as
substrate for LPL was observed, suggesting an additional, yet
unrecognized benefit of HD.
RESULTS
Effects of HD on biochemical parameters
Biochemical parameters for the 28 patients are given in
Table 1. Before HD, urea and creatinine levels in plasma were
250 and 800% above the normal physiological range,
respectively. As expected, the 4-h dialysis procedure induced
an approx. 70% decrease in urea and creatinine concentra-
tions. Total protein concentration in plasma was increased by
10% after HD (Po0.001 Wilcoxon), reflecting the hemo-
concentration that is induced by fluid losses.
As compared with normal values, total cholesterol, HDL
cholesterol, and apo A-I concentrations were in the normal
physiological range in patients before HD, whereas the mean
TG concentration was increased (Table 1). Interestingly, all
the plasma lipid parameters were increased in similar
proportions (approx. 10%) after HD (Po0.001 Wilcoxon),
and levels of one given parameters before and after HD were
remarkably similar when values were corrected for variation
in total protein concentration (Table 1). Overall, these data
indicate that the dialysis procedure per se has no selective
impact on standard lipid parameters, and concomitant 10%
increases in total cholesterol, TGs, HDL cholesterol, and total
proteins after HD were actually due to hemoconcentration.
Apolipoprotein C concentrations before and after HD
Plasma concentrations of apolipoproteins C-I, C-II and C-III
were determined before and after HD by a specific enzyme-
linked immunosorbent assay (ELISA) (apoC-I) or by
immunoturbidimetry (apoC-II and apoC-III). Values were
expressed either as apolipoprotein concentration or as
apolipoprotein to total protein ratio in order to take into
account the hemoconcentration phenomenon. Whereas
apoC-II concentrations were significantly increased after
HD (Table 2, Figure 1), no significant change was observed
when values were corrected for hemoconcentration. In
contrast, although no significant changes in the apoC-III
concentration were observed before and after HD, a slight,
significant decrease appeared when values were corrected by
hemoconcentration, indicating a significant loss of apoC-III
during dialysis. Apo C-I concentrations decreased readily
after dialysis and magnitude of changes was even greater
when corrected for hemoconcentration with approximately a
20% decrease as compared with values before HD
(Po0.0001). Concentrations of apo Cs (apo C-I, apo C-II,
apo C-III) did not differ between two groups of patients with
(n¼ 9) or without (n¼ 19) hypolipidemic medication
Table 1 | Biochemical and plasma lipid parameters in pre- and post-dialysis plasmas
Before hemodialysis After hemodialysis Normal range
Urea (mmol/l) 2575.8 7.9272.44a 3.2–7.5
Creatinine (mmol/l) 9267185.4 355795.9a 71–133
Protein (g/l) 6977.1 79710.8a 63–82
Total cholesterol (mmol/l) 4.2871.05 4.6971.06a 3.1–6.2
Total cholesterol/protein (mmol/g) 61.1713.0 60.5713.9
Triglycerides (mmol/l) 2.0471.13 2.2671.14a 0.30–1.60
Triglycerides/protein (mmol/g) 29.6715.8 28.8714.3
HDL cholesterol (mmol/l) 1.0670.28 1.2270.34a 0.90–1.60
HDL cholesterol/protein (mmol/g) 15.474.2 15.674.4
Apolipoprotein A-I (g/l) 1.0370.20 1.1970.33a 1.10–1.80
Apo A-I/protein (mg/g) 14.8472.80 15.1573.75
HDL, high-density lipoprotein.
Blood samples were collected immediately before and after hemodialysis. Urea, creatinine, and total protein were measured on Vitros 950 analyzer. Total cholesterol,
triglycerides, apolipoprotein A-I, and HDL cholesterol were measured on a Dimension X-pand analyzer as described in ‘Materials and methods’. Statistics by Wilcoxon test.
aPo0.0001 vs before hemodialysis.
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(predialysis: 1.7270.86 vs 2.2171.00 mg apo C-I/g protein,
respectively; NS. Post-dialysis: 1.4270.62 vs 1.6770.65 mg
apo C-I/g protein, respectively; NS). When patients with an
hypolipidemic medication were excluded, a significant
decrease in apoC-I after HD was still observed
(2.2171.00 mg apo C-I/g protein before dialysis vs
1.6770.65 mg apo C-I/g protein after dialysis; Po0.01),
indicating that differences in the whole population studied,
before and after dialysis, were independent of treatments.
HD reduced VLDL-bound but not HDL bound apoC-I
In the plasma compartment, ApoC-I is mainly bound to
HDL, and to a lesser extent to VLDL. In order to determine
whether HD has a differential impact on ApoC-I contents of
HDL and VLDL, both lipoprotein subclasses were isolated
and apoC-I was determined in each fraction by ELISA.
As shown, in Figure 2, the apoC-I content of HDL (expressed
as apoC-I to apo A-I ratio) was the same before and after HD,
whereas the apoC-I content of VLDL (expressed as apoC-I to
apo B ratio) was markedly decreased (by 30%), as compared
with values before HD (Figure 3). This was confirmed by
polyacrylamide gradient gel electrophoresis and Western blot
analyses, showing a marked reduction in VLDL apoC-I after
HD (Figures 4a and b). ApoC-III in VLDL and HDL was also
determined in pre- and post-dialysis plasmas. As shown in
Table 2, slight decreases of the apoC-III concentrations were
observed in both VLDL and HDL but differences did not
reach the statistical significance. Time course analysis of the
apo C-I content of VLDL was performed in patients
undergoing HD at times 0, 2, and 24 h after initiation of
the dialysis session. Again, a significant, 20% decrease in the
apo C-I content of VLDL was found 2 h after initiation of
HD, with normalization of the apo C-I levels after 24 h
(Figure 5).
CETP mass concentration and activity before and after HD
As apoC-I was recently identified as a major physiological
inhibitor of CETP, we determined whether CETP activity was
modified by HD. As shown in Table 3, whereas CETP mass
concentration was significantly increased after HD, no
changes in CETP activity or CETP mass concentration were
observed in total plasma before and after dialysis when
corrected for hemoconcentration.
Effect of apoC-I on the ability of VLDL to act as substrates for
CETP
As HD decreased VLDL-apoC-I but not HDL-apoC-I, we
directly measured the ability of pre- and post-dialysis VLDL
to act as substrate for CETP. As shown in Figure 6, the rate of
exchange of cholesteryl esters was similar with pre- and post-
dialysis VLDL. These data suggest therefore that unlike HDL
apoC-I,20 VLDL apoC-I is not a major determinant of their
ability to interact with CETP. In order to confirm further that
the CETP inhibitory potential was lost when apoC-I is
associated with VLDL, CETP inhibition was measured at
different apoC-I to human VLDL ratio. In the presence of
constant amounts of apoC-I, but increasing amounts of
VLDL, apoC-I inhibited CETP only at very high, extra
physiological ratio (apoC-I to TG molar ratio 0.06 to 0.03),
whereas at lower, physiological apoC-I to VLDL ratios
(apoC-I to TG molar ratio below 0.015) no CETP blockade
occurred (Figure 7).
Table 2 | Apolipoprotein C concentrations in pre- and post-
dialysis plasmas
Before
hemodialysis
After
hemodialysis
Plasma apo C-I (mg/l) 137.7758.4 124.4746.5a
Plasma apo C-I (mg/g prot) 2.0370.97 1.6070.64b
Plasma apo C-II (mg/l) 36.1710.7 39.5712.3a
Plasma apo C-II (mg/g prot) 0.5370.17 0.5070.14
Plasma apo C-III (mg/l) 176749 180751
Plasma apo C-III (mg/g prot) 2.5970.79 2.2970.61a
HDL apo C-I (mg/l) 19.275.4 22.076.2a
HDL apo C-I (mg/g apo A-I) 18.374.9 18.374.5
HDL apo C-III (mg/l) 107738 103739
HDL apo C-III (mg/g apo A-I) 103736 85733
VLDL apo C-I (mg/l) 87.7758.7 58.0752.6a
VLDL apo C-I (mg/g apo B) 1877113 1047101b
VLDL apo C-III (mg/l) 91752 133787
VLDL apo C-III (mg/g apo B) 217780 2057134
HDL, high-density lipoprotein; VLDL, very low-density lipoprotein.
Blood samples were collected immediately before and after hemodialysis. HDL and
VLDL were isolated by sequential ultracentrifugation. Apolipoprotein C-I concentra-
tions were determined by a specific ELISA. Apo A-I, Apo B, ApoC-II, and apoC-III
concentrations were determined by immunoturbidimetric assays on a Dimension
X-Pand.
aPo0.01 vs before hemodialysis.
bPo0.001 vs before hemodialysis.
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Figure 1 | ApoC-I content in total blood plasma before and after
HD. Blood samples were collected immediately before and after HD.
Apolipoprotein C-I concentrations were determined by a specific
ELISA as described in ‘Materials and Methods’. Results are expressed
as apoC-I to total protein ratio. Values are mean7s.d. (bold type).
*Po0.01 Wilcoxon test.
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Post-dialysis VLDL is better substrate for LPL than
pre-dialysis VLDL
Besides CETP, apoC-I is able to modulate the activity of
several enzymes involved in lipoprotein metabolism. In
particular, recent studies have demonstrated that the
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Figure 2 | ApoC-I content of HDL before and after HD. Blood
samples were collected immediately before and after HD, and HDL
were isolated by sequential ultracentrifugation as described in
‘Materials and Methods’. Apolipoprotein C-I concentrations were
determined by a specific ELISA as described in ‘Materials and
Methods’. Results are expressed as apoC-I to apoA-I ratios. Values are
mean7S.D. (bold type). NS: no significant differences by Wilcoxon
test.
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Figure 3 | ApoC-I content of VLDL before and after HD. Blood
samples were collected immediately before and after HD, and VLDL
were isolated by sequential ultracentrifugation as described in
‘Materials and Methods’. Apolipoprotein C-I concentrations were
determined by a specific ELISA as described in ‘Materials and
Methods’. Results are expressed as apoC-I to apoB ratio. Values are
mean7s.d. (bold type). *Po0.01 Wilcoxon test.
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Figure 4 | Apolipoprotein composition of pre- and post-dialysis
VLDL. VLDL were isolated by sequential ultracentrifugation from
pre- or post-dialysis plasmas, and their apolipoprotein contents were
analyzed on an sodium dodecyl sulfate-polyacrylamide gradient gel
(a) by coomassie staining or (b) by Western blot analysis using anti
apolipoprotein C-I antibodies. 1: Molecular weight markers, 2:
purified apoC-I, 3: pre-dialysis VLDL, 4: post-dialysis VLDL.
170
*
150
130
110
90
70
50
30
R
el
at
ive
 le
ve
ls
 o
f
a
po
C-
I i
n 
VL
D
L 
(%
)
T0 T2 T24
Time (h)
Figure 5 | Time course analysis of the apo C-I content of VLDL.
Blood samples were collected before (t¼ 0) and after the dialysis
session (2 and 24 h). VLDL were isolated by sequential
ultracentrifugation, and apolipoprotein C-I concentrations were
determined by a specific ELISA as described in ‘Materials and
Methods’. ApoC-I level in VLDL was compared to 100%, t¼ 0 controls.
Values are mean7s.d. *Po0.01 vs T0; Wilcoxon test.
874 Kidney International (2007) 72, 871–878
o r i g i n a l a r t i c l e G Dautin et al.: Plasma apolipoprotein C-I concentration reduction
potential hyperlipidemic effect of apoC-I overexpression was
linked to its ability to inhibit LPL.22 Therefore, we measured
the ability of pre- and post-dialysis VLDL to act as substrate
for LPL by an in vitro assay. LPL activity was expressed as the
amount of free fatty acids (FFA) released from VLDL
incubated with purified LPL. As shown in Figure 8, a
significant, twofold increase in FFA release was observed with
post-dialysis VLDL as compared with pre-dialysis VLDL
(Po0.01). These data indicate therefore that, unlike for
CETP activity, the association of apoC-I with VLDL in
proportions found in vivo (apoC-I to TG molar ratio of
approximately 0.01) has the ability to modify the interaction
of VLDL with LPL.
DISCUSSION
Most of dialysis membranes are permeable to small size
proteins and significant losses of small proteins such as b2
microglobulin (MW¼ 11 800 Da) are known to occur during
HD.25,26 As compared with b2 microglobulin, apolipoprotein
Cs are even smaller proteins (molecular weight ranging from
6500 to 8500 Da). In addition, and despite their amphipatic
nature and their association with large size lipoproteins, apo
Cs are able to exchange freely between lipoprotein particles
by diffusion through the aqueous phase.24 Overall, it appears
that apoCs are most likely to pass easily through and/or to
adsorb on dialysis membranes and then to be lost partly
during HD. The latter point was specifically addressed in this
study by measuring plasma apoC content before and after
HD of patients with chronic renal failure. Among apolipo-
protein Cs, plasma apoC-I concentration underwent the
most pronounced decrease during the HD procedure, with
only a slight decrease in apoC-III and no change in apoC-II.
In addition, levels of apolipoproteins with higher molecular
weight, such as apo A-I remained unchanged after HD.
Interestingly, it has been demonstrated that the adsorption/
filtration of proteins during HD is dependent not only on
Table 3 | CETP activity and mass concentration in pre- and post-dialysis plasmas
CETP activity
fluorescence a.u.
Specific CETP activity
(fluorescence/mg CETP)
CETP mass
(mg/l)
CETP to total protein
ratio (lg/g protein)
Before hemodialysis 24447486 12287189 2.0470.43 29.875.9
After hemodialysis 25397496 11437214 2.2870.51a 28.677.5
Blood samples were collected immediately before and after hemodialysis. CETP activity and mass were measured as described in Materials and Methods. Statistics by
Wilcoxon test.
aPo0.0001 vs before hemodialysis.
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Figure 6 | Comparison of the ability of pre- or post-dialysis VLDL
to interact with CETP. VLDL were isolated by sequential
ultracentrifugation from pre- or post-dialysis plasmas. Cholesteryl
ester transfer activity was determined as the rate of transfer of
fluorescent NBD-cholesteryl esters from labeled liposome donors to
HDL acceptors in the presence of a purified CETP fraction (final
protein concentration, 8 mg) along a 3-h incubation period at 371C
(see ‘Materials and Methods’). Blank values were obtained with
homologous, incubated mixtures to which no purified CETP was
added. Values are mean7s.d. of three determinations. No significant
differences were observed by Wilcoxon test.
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Figure 7 | Effect of VLDL concentrations on the CETP inhibitory
potential of apoC-I. Cholesteryl ester transfer activity was
determined as the rate of transfer of fluorescent NBD-cholesteryl
esters from labeled liposome donors (phospholipids, 5 mmol/l) to
VLDL acceptors (range, 10–500 mmol/l) in the presence of purified
CETP (8 mg) in a final volume of 200 ml. Incubations were conducted
for 3 h at 371C in the absence or in the presence of purified apoC-I
(concentration, 0.5 mmol/l). ApoC-I to TGs ratio was calculated by
taking into account both the quantity of purified apo C-1 added to
the incubation media (0.5 mM) and the VLDL-associated apoC-I
(0.012 mol apo C1/mole TG). Percentage of CETP inhibition (vertical
bars) was calculated by comparing the initial transfer rate in the
presence of apoC-I to the initial transfer rate with no apoC-I added.
Transfer rates were determined from the linear, initial portion of the
time course curves. Values are mean7s.d. of three determinations.
*Significantly different from mixtures containing 0.5 mmol/l of apoC-I,
Po0.05; Mann–Whitney test.
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protein size but also on electrostatic interactions between
negative charges of dialysis membranes and positively
charged amino-acid residues.25,27 As compared with other
apoCs, apoC-I displays the lowest molecular weight
(6500 Da) and the highest isoelectric point (pHi, 8.5) due
to the presence of a cluster of lysine residues in its C-terminal
region.28 Therefore, it is plausible that the higher propensity
of apoC-I to be cleared during HD is linked to these unique
physicochemical properties. In support of this view, Ishikawa
et al. have recently identified apolipoprotein C-I as a major
protein adsorbed on polysulfone membranes during HD.
This would suggest that adsorption on the dialysis mem-
brane, rather that direct clearance is the primary mechanism
accounting for the apo C-I decrease during HD.29
Interestingly, the extent of apoC-I loss during HD seems
to be dependent on its localization among circulating
lipoproteins. Indeed, plasma apoC-I was significantly de-
creased (by approximately 30%) only in the VLDL fraction
after HD, whereas in the meantime HDL-apoC-I levels
remained constant. Although the molecular mechanism
accounting for the difference in VLDL-bound and HDL-
bound apoC-I to undergo filtration during HD is unclear, it
might relate in some way to marked differences in half-life
and stability of VLDL and HDL classes in the blood stream.
Indeed, and as assessed earlier through kinetic studies, mean
residence time of HDL in human plasma (a few days) is
considerably longer than mean residence time of VLDL (a
few hours).30,31 High turnover of VLDL is due to fast TG
hydrolysis, which leads sequentially from VLDL to inter-
mediate density lipoprotein, and then to LDL. Interestingly,
rapid VLDL lipolysis and associated lipid core shrinkage
produce, among other events, the release of loosely bound,
surface components, among them apoprotein Cs.32 In the
end, the dissociated, lipoprotein-free apoC-I is likely to be
more prone to filtration through dialysis membranes than
HDL-bound apoC-I. In addition, it must be emphasized that
the extent of apoC-I release from the VLDL surface might
well have been increased by heparin injection during HD.
Indeed, heparin injection is known to disrupt the anchoring
of LPL at the vessel wall, thus increasing lipolysis activity and,
as a consequence, apoC-I release from the VLDL surface.
Recently, apoC-I was identified as a physiological inhibitor
of CETP through its ability to modify the electrostatic charge
properties of circulating HDL.33 In this study, HDL apoC-I
content did not differ before and after HD, and this was
accompanied with no change in CETP mass and activity in
total plasma when corrected for hemoconcentration. In
contrast, post-dialysis VLDL was shown to contain fewer
apoC-I molecules than pre-dialysis VLDL, but again in the
absence of changes in CETP activity (Figure 6). The latter
point might well reflect the inability of physiological levels of
apoC-I to produce significant changes in the electrostatic
charge properties of VLDL, which are very large, lipid-rich/
protein-poor, and slow-migrating lipoproteins as compared
with HDL. In other words, apoC-I would be a potent
inhibitor of CETP when bound to HDL (as shown in earlier
studies from our group20,33), but with no inhibitory potential
when bound to the large, lipid-rich VLDL. In direct and
strong support of the latter view, we observed through in
vitro manipulations that VLDL-bound apoC-I had the ability
to inhibit CETP activity only at high levels, which went
beyond the range of apoC-I to VLDL ratio that is observed in
humans. This study indicates than HD would actually
produce a selective decrease only in the inactive form of
apoC-I (i.e. VLDL-bound apoC-I), and not in the inhibitory,
HDL-bound apoC-I fraction, thus resulting in no change in
plasma CETP activity.
In addition to its role in CETP activity modulation, apoC-
I was found in previous studies to constitute a significant
inhibitor of LPL activity.22 In vitro enrichment of VLDL-like
particles with apoC-I induces a concentration-dependent
inhibition of the LPL-mediated FFA release.22 In addition,
and in support of the physiological relevance of this function,
recent studies demonstrated that the hyperlipidemia
observed in apoC-I transgenic mice was mainly due to an
apoC-I-mediated inhibition of LPL activity.22 Interestingly, a
significant increase in the ability of VLDL to act as substrate
for LPL was observed in this study after HD, and the mean
35% increase in LPL activity after HD was of similar
magnitude than the concomitant 40% decrease in apoC-I
content of VLDL. Beyond earlier studies, which were
conducted either in vitro or in vivo in apoC-I-KO or apoC-
I transgenic mouse models, this study brings the first, direct
evidence for apoC-I abnormalities in a population of patients
undergoing HD. Fewer amounts of apoC-I in VLDL, as
observed in the patients with chronic renal failure immedi-
ately after HD, would secondarily lead to a significant rise in
the ability of these particles to act as substrate for LPL.
Finally, apoC-I loss might contribute to face the reduction in
LPL activity and the accumulation of TG-rich lipoproteins
Before hemodialysis
After hemodialysis
0.500
0.400
0.300
0.200
0.100
0.000
1 2
Subject number
Fr
e
e
 fa
tty
 a
cid
 (m
mo
l/l)
3 4 5 6 7 8 Mean
*
Figure 8 | Comparison of the ability of pre- or post-dialysis VLDL
to act as substrates for LPL. VLDL were isolated by sequential
ultracentrifugation from pre- or post-dialysis plasmas. VLDL (60 nmol
TGs/assay) were incubated in the presence of purified LPL (purified
from bovine milk, Sigma) in 10ml Tris-buffer (0.1 M Tris, pH 8.5) at
371C for 6 min. The reaction was stopped by the addition of Triton
X-100, vortexing and cooling on ice. A blank sample was obtained in
parallel by adding Triton before the addition of LPL and maintenance
on ice. Aliquots of the samples were used to determine FFA
concentrations in triplicate using an enzymatic assay. LPL activity was
expressed as the amount of FFA released from VLDL during the
incubation period. Values are mean7s.d. Po0.05 Wilcoxon test.
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that are major components of chronic renal failure.34 In
addition, it can be postulated that regular apoC-I clearance
by HD might contribute to the reduction in triglyceridemia
that was reported to occur in dialyzed patients as compared
with undialyzed patients.35 The impact of decrease in VLDL-
apoC-I levels on TG metabolism and cardiovascular disease
in high-risk patients with chronic renal failure will deserve
further attention in longitudinal studies of larger populations
of patients.
MATERIALS AND METHODS
Patients
Patients (14 females and 14 males; 61.2714.4 years old) were
recruited at the Hemodialysis Center of the University Hospital of
Dijon (CHU Dijon, France). Four patients (two females and two
males, 59.5712 years old) were recruited at the Department of
Nephrology, Dialysis, and Renal Transplantation, CHU Saint
Jacques, Besanc¸on. A written informed consent was obtained from
each subject before the study. All the subjects were suffering from
chronic renal failure, and they underwent 4-h sessions of membrane
HD two or three times a week. The mean time since the beginning of
HD was 5.574.8 years. Twenty-five percent of the patients were
diabetics and received insulin or oral antidiabetic drugs. Nine
patients received hypolipidemic drugs. Venous blood samples were
collected just before, and immediately after HD. Plasma was
centrifugated at low speed and stored at 801C until analysis. All
the patients were heparanized. Dialysis was conducted by using an
FX8 membrane (Fresenius Medical Care, Bad Homburg Germany;
ultrafiltration coefficient¼ 12) (n¼ 10), an FX60s membrane
(Fresenius Medical Care, ultrafiltration coefficient¼ 40) (n¼ 4), or
a Nephral 300 or 400 ST membrane (Hospal, Lyon, France;
ultrafiltration coefficient¼ 40 or 50) (n¼ 22). No differences were
observed between these groups, with similar evolution of lipid and
apoprotein concentrations before and after dialysis. Therefore,
results combining data from these groups are presented in this
paper.
Biochemical and lipid analysis
Urea, Creatinine, and total protein concentrations were measured
on a Vitros 950 analyzer using colorimetric or enzymatic assays
following the procedures provided by the manufacturer (Ortho-
clinical diagnostic, Issy les moulineaux, France). Total cholesterol,
HDL cholesterol, and TGs were measured by enzymatic methods on
a Dimension X-Pand analyzer (Dade Behring, Paris, France)
Apolipoprotein B, A-I, C-II, and C-III concentrations were
measured by commercial immunoturbidimetric assays following
the procedure provided by the manufacturers (apo A-I and apo B:
Dade-Behring, apoC-II, and ApoC-III: Diasys, Bouffemont, France).
Cholesteryl ester transfer protein mass concentration and
activity
CETP mass levels were determined by a specific immunoassay
with TP2 anti-CETP monoclonal antibodies.36 Purified CETP
was obtained from human plasma by using a sequential chromato-
graphy procedure.20 Cholesteryl ester transfer activity was deter-
mined as the rate of transfer of fluorescent 7-nitrobenz-2-oxa-
1,3-diazol-4-yl (NBD)-cholesteryl esters from labeled liposome
donors (phospholipids, 5 mmol/l) to VLDL acceptors (range,
10–500 mmol/l) in the presence of purified CETP (8mg) in a final
volume of 200ml. Incubations were conducted for 3 h at 371C in the
absence or in the presence of purified apoC-I (concentration,
0.5 mmol/l).33 ApoC-I to TG ratios were calculated by taking into
account both the amount of purified apoC-I added to the
incubation media (0.5 mmol/l), and the VLDL-associated apoC-I
(0.012 mol apoC-I/mole TG). Percentage of CETP inhibition was
calculated as the ratio of transfer rates in the presence of apoC-I to
corresponding transfer rates with no apoC-I added. Transfer rate
values were determined from the linear, initial portion of the time
course transfer curves.
Determination of apoC-I concentration by ELISA
Competitive ELISA for apoC-I was set up according to the general
procedure used in our laboratory to quantify apoA-IV.36 Polyclonal
antibodies to human apoC-I were raised in a rabbit injected four
times with 250mg of human apoC-I that had been purified to
homogeneity as described previously.20 The absorbance was
measured at 490 nm. Eight dilutions (apoC-I concentrations from
about 0.0024 to 27.4 mg/l) were used to draw a calibration curve for
each plate.
Preparation of VLDL by ultracentrifugation
VLDL were ultracentrifugally isolated from patient plasmas as the
do1.006 fraction, with two 1.40-h, 120 000-r.p.m. spins in a 70.Ti
rotor in an L90-K ultracentrifuge (Beckman, Palo Alto, CA, USA).
Apo B content of the VLDL was determined by an immunoturbi-
dimetic assay on a Dimension X-Pand analyzer.
LPL activity
The ability of VLDL to act as a substrate for LPL was determined as
described previously.37 Briefly, VLDL (60 nmol TGs/assay) were
diluted in 0.1 M Tris buffer (pH 8.5), containing 1% (w/v) fatty acid-
free bovine serum albumin (final volume 100ml). The incubation
was started by adding 0.84 ml LPL (purified from bovine milk,
Sigma, Saint Louis, MI, USA) in 10 ml Tris-buffer (0.1 M Tris, pH 8.5)
to 100 ml VLDL-TG, followed by incubation at 371C. The reaction
was stopped after 6 min by the addition of Triton X-100 (1% (v/v),
final concentration), vortexing and cooling on ice. A blank sample
was obtained in parallel by adding Triton before the addition of LPL
and it was maintained on ice. Finally, FFA concentrations were
determined in triplicate using an enzymatic assay (NEFA-C Wako,
Osaka, Japan).
Apolipoprotein analysis by polyacrylamide gradient gel
electrophoresis
VLDL apolipoproteins were delipidated with ethanol/ether (3:2),
diluted in the sample buffer containing a reducing agent and applied
on 4–12% NuPage Bis Tris Novex sodium dodecyl sulfate-
polyacrylamide gels as recommended by the manufacturer (Invitro-
gen, Cergy Pontoise, France). Proteins were stained with Coomassie
Brilliant Blue G-250, and the apparent molecular weights of
individual protein bands were determined by reference to protein
standards (Mark12, Invitrogen).
Western blot analysis of apolipoprotein C-I in VLDL
Samples were applied on 4–12% NuPage Bis Tris Novex sodium
dodecyl sulfate-polyacrylamide gels as described above and were
further transferred to a nitrocellulose membrane. The resulting blots
were blocked overnight at 41C with 10% low fat dried milk in
Tris-buffered saline containing 0.1% Tween, and washed with
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Tris-buffered saline-Tween. The blots were incubated successively
with polyclonal anti-apoC-I antibodies and with peroxidase-
conjugated anti-goat antibodies (Sigma) as described previously.
Blots were finally developed using an ECL kit20 (GE Healthcare,
Uppsala, Sweden).
Statistical analyses
Wilcoxon test was used to determine the significance between the
data means.
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